Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL ANDREW SINGER

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1912902651
CMS profile
177231
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$396,744.79

356 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 8; records 101–150 of 356 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL ANDREW SINGER

NPI 1912902651 · CMS profile ID 177231

Allopathic & Osteopathic Physicians / Ophthalmology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 8; records 101–150 of 356 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912902651?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL ANDREW SINGER, NPI 1912902651, CMS profile ID 177231. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 356 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912902651?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MICHAEL ANDREW SINGER, NPI 1912902651, CMS profile ID 177231. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 356 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912902651?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MICHAEL ANDREW SINGER, NPI 1912902651, CMS profile ID 177231, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 356 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1912902651?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

356 matching records · $396,744.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 356 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 356.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $5.9808/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150171 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $4,300.0008/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709076671 CMS
Allergan Inc. $128.7508/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150109 CMS
Regeneron Healthcare Solutions, Inc. $5.5208/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673478133 CMS
Regeneron Healthcare Solutions, Inc. $7.4808/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673478135 CMS
Regeneron Healthcare Solutions, Inc. $44.0008/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673478137 CMS
Regeneron Healthcare Solutions, Inc. $100.0008/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673478139 CMS
Allergan Inc. $9.4408/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150063 CMS
Allergan Inc. $50.0008/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150065 CMS
Allergan Inc. $11.8008/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150069 CMS
Allergan Inc. $502.9808/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150071 CMS
Allergan Inc. $7.7108/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150075 CMS
Allergan Inc. $5.4108/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150077 CMS
Allergan Inc. $502.3008/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150081 CMS
Allergan Inc. $210.2008/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150085 CMS
Allergan Inc. $217.3808/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150087 CMS
Allergan Inc. $50.0008/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150091 CMS
Allergan Inc. $8.0008/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150093 CMS
Allergan Inc. $5.0008/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150097 CMS
Allergan Inc. $63.6608/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150099 CMS
Allergan Inc. $5,000.0008/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150103 CMS
Allergan Inc. $126.3408/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150105 CMS
Regeneron Healthcare Solutions, Inc. $336.3807/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673478123 CMS
Regeneron Healthcare Solutions, Inc. $28.0807/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673478125 CMS
Regeneron Healthcare Solutions, Inc. $20.4107/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673478127 CMS
Regeneron Healthcare Solutions, Inc. $44.0007/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673478129 CMS
Regeneron Healthcare Solutions, Inc. $100.0007/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673478131 CMS
Novartis Pharmaceuticals Corporation $307.0007/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118609 CMS
Novartis Pharmaceuticals Corporation $31.4107/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118612 CMS
Novartis Pharmaceuticals Corporation $1,075.0007/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118621 CMS
Genentech, Inc. $167.0007/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681183379 CMS
Allergan Inc. $49.3907/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150050 CMS
Allergan Inc. $24.7507/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150055 CMS
Allergan Inc. $75.7007/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150057 CMS
Allergan Inc. $3,750.0007/26/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671150061 CMS
EyePoint Pharmaceuticals US, Inc. $148.8507/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698074913 CMS
Aerie Pharmaceuticals, Inc. $134.6407/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662036857 CMS
Novartis Pharmaceuticals Corporation $221.8707/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118479 CMS
Novartis Pharmaceuticals Corporation $210.3007/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118483 CMS
Novartis Pharmaceuticals Corporation $6,450.0007/25/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118487 CMS
Novartis Pharmaceuticals Corporation $5.2507/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118491 CMS
Novartis Pharmaceuticals Corporation $98.4007/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118495 CMS
Novartis Pharmaceuticals Corporation $647.9707/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118459 CMS
Novartis Pharmaceuticals Corporation $8,200.0007/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118463 CMS
Novartis Pharmaceuticals Corporation $87.4007/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118467 CMS
Novartis Pharmaceuticals Corporation $576.2307/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118471 CMS
Novartis Pharmaceuticals Corporation $25.8507/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118537 CMS
Novartis Pharmaceuticals Corporation $280.0007/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660118607 CMS
Regeneron Healthcare Solutions, Inc. $6,132.0007/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673478121 CMS
Aerie Pharmaceuticals, Inc. $94.0507/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662036853 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $396,744.79 356
PY2020 $90,562.68 79
PY2021 $160,039.64 135
PY2022 $379,716.13 313
PY2023 $302,241.35 255
PY2024 $213,019.73 158
PY2025 $238,137.52 132

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $7,657.64 13
PY2025 Principal investigator $354,634.96 121
PY2024 Recipient $18,302.62 17
PY2024 Principal investigator $258,007.39 68
PY2023 Recipient $13,668.15 10
PY2023 Principal investigator $278,181.85 39
PY2022 Principal investigator $302,206.46 28
PY2021 Recipient $8,280.88 3
PY2021 Principal investigator $515,213.99 38
PY2020 Recipient $22,086.55 7
PY2020 Principal investigator $436,403.74 46
PY2019 Recipient $6,875.54 3
PY2019 Principal investigator $324,037.99 39

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

134 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $3,610.60 12/24/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693497
Principal investigator 1 Ocular Therapeutix, Inc. $5,162.40 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $624.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $82.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $109.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280132
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280134
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $72.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $169.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280144
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280146
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $69.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280150
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $324.00 12/24/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184280152
Principal investigator 1 Boehringer Ingelheim International GmbH $7,000.00 12/19/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693495
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/19/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693499
Principal investigator 1 Boehringer Ingelheim International GmbH $4,000.00 12/19/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693501
Principal investigator 1 Boehringer Ingelheim International GmbH $1,904.00 12/19/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693503
Principal investigator 1 Boehringer Ingelheim International GmbH $3,361.40 12/11/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693493
Principal investigator 1 Ocular Therapeutix, Inc. $10,602.00 12/01/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234930
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 11/19/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693507
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 11/19/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693509
Principal investigator 1 Boehringer Ingelheim International GmbH $67.28 11/19/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693511
Principal investigator 1 Ocular Therapeutix, Inc. $7,173.90 11/19/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234926
Principal investigator 1 Genentech, Inc. $10,322.00 11/12/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211623212
Principal investigator 1 SANOFI US SERVICES INC. $9,600.00 11/12/2025 Non-covered Recipient Entity
Medical Center Opthalmology Associate
Age-related macular degeneration No dispute reported 06/30/2026 1226107497
Principal investigator 1 SANOFI US SERVICES INC. $3,705.00 11/12/2025 Non-covered Recipient Entity
Medical Center Opthalmology Associate
Age-related macular degeneration No dispute reported 06/30/2026 1226107527
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 11/12/2025 Non-covered Recipient Entity
Medical Center Opthalmology Associate
Age-related macular degeneration No dispute reported 06/30/2026 1226107537
Principal investigator 1 Ocular Therapeutix, Inc. $12,917.70 11/05/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234921
Principal investigator 1 Ocular Therapeutix, Inc. $5,162.40 10/29/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234917
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 10/27/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693505
Principal investigator 1 Boehringer Ingelheim International GmbH $3,361.40 10/22/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693483
Principal investigator 1 Genentech, Inc. $3,056.00 10/17/2025 Non-covered Recipient Entity
MEDICAL CTR OPHTHALMOLOGY ASSOC LLP
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211623251
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $171.60 10/16/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225409942
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,120.00 10/16/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410030
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 10/16/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410262
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,476.80 10/16/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225410278
Principal investigator 1 Genentech, Inc. $2,210.00 10/16/2025 Non-covered Recipient Entity
MEDICAL CTR OPHTHALMOLOGY ASSOC LLP
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211623246
Principal investigator 1 Genentech, Inc. $14,174.00 10/10/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211623210
Principal investigator 1 Boehringer Ingelheim International GmbH $1,376.20 10/09/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693481
Principal investigator 1 Boehringer Ingelheim International GmbH $1,376.20 10/09/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693487
Principal investigator 1 Boehringer Ingelheim International GmbH $1,376.20 10/09/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693489
Principal investigator 1 Boehringer Ingelheim International GmbH $1,376.20 10/09/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693491
Principal investigator 1 Boehringer Ingelheim International GmbH $4,180.40 10/06/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693485
Principal investigator 1 Genentech, Inc. $2,869.00 09/26/2025 Non-covered Recipient Entity
MEDICAL CTR OPHTHALMOLOGY ASSOC LLP
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211623241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,062.00 09/25/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,500.00 09/25/2025 Non-covered Recipient Entity
MEDICAL CENTER OPHTHALMOLOGY ASSOCIATES
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184242557
Principal investigator 1 Ocular Therapeutix, Inc. $5,162.40 09/24/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234914
Principal investigator 1 Boehringer Ingelheim International GmbH $3,810.80 09/15/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693479
Recipient F. Hoffmann-La Roche AG $565.91 08/29/2025 Covered Recipient Physician Faricimab DME Long Term Extension Rhone X No dispute reported 06/30/2026 1211537768
Principal investigator 1 Ocular Therapeutix, Inc. $6,396.30 08/29/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234910
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 08/26/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693469
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 08/26/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693471
Principal investigator 1 Boehringer Ingelheim International GmbH $657.00 08/26/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693473
Principal investigator 1 Boehringer Ingelheim International GmbH $169.36 08/26/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693475
Principal investigator 1 Boehringer Ingelheim International GmbH $3.66 08/26/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693477
Principal investigator 1 Boehringer Ingelheim International GmbH $5,768.00 08/25/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693447
Principal investigator 1 Boehringer Ingelheim International GmbH $3,931.20 08/14/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693453
Principal investigator 1 Boehringer Ingelheim International GmbH $3,361.40 08/04/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693445
Principal investigator 1 Boehringer Ingelheim International GmbH $4,715.20 08/04/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693449
Principal investigator 1 Boehringer Ingelheim International GmbH $1,695.40 08/04/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693451
Principal investigator 1 Boehringer Ingelheim International GmbH $4,827.20 08/04/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693455
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 07/28/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693461
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 07/28/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693463
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 07/28/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693465
Principal investigator 1 Boehringer Ingelheim International GmbH $81.20 07/28/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693467
Principal investigator 1 Ocular Therapeutix, Inc. $6,883.20 07/25/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234906
Principal investigator 1 Genentech, Inc. $2,330.28 07/10/2025 Non-covered Recipient Entity
MEDICAL CTR OPHTHALMOLOGY ASSOC LLP
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211623238
Principal investigator 1 Genentech, Inc. $3,755.00 07/07/2025 Non-covered Recipient Entity
MEDICAL CTR OPHTHALMOLOGY ASSOC LLP
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211623234
Principal investigator 1 Ocular Therapeutix, Inc. $7,704.90 07/02/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234902
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693443
Principal investigator 1 Genentech, Inc. $3,333.00 06/25/2025 Non-covered Recipient Entity
MEDICAL CTR OPHTHALMOLOGY ASSOC LLP
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211623216
Principal investigator 1 Genentech, Inc. $33,770.00 06/25/2025 Non-covered Recipient Entity
MEDICAL CTR OPHTHALMOLOGY ASSOC LLP
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211623220
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 06/24/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693437
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693439
Principal investigator 1 Boehringer Ingelheim International GmbH $12.76 06/24/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693441
Principal investigator 1 Boehringer Ingelheim International GmbH $3,931.20 06/18/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693421
Principal investigator 1 Boehringer Ingelheim International GmbH $4,180.40 06/16/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693423
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693459
Principal investigator 1 Boehringer Ingelheim International GmbH $3,810.80 05/29/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693427
Principal investigator 1 Boehringer Ingelheim International GmbH $4,827.20 05/29/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693429
Principal investigator 1 Ocular Therapeutix, Inc. $7,704.90 05/28/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234899
Principal investigator 1 ANI Pharmaceuticals, Inc. $9,697.30 05/12/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
New Day Study No dispute reported 06/30/2026 1248567443
Principal investigator 1 Boehringer Ingelheim International GmbH $3,717.00 05/05/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693425
Recipient F. Hoffmann-La Roche AG $266.56 05/05/2025 Covered Recipient Physician Faricimab DME Long Term Extension Rhone X No dispute reported 06/30/2026 1211537772
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693431
Principal investigator 1 Ocular Therapeutix, Inc. $16,308.90 04/30/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234895
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,337.40 04/28/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225402933
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,978.30 04/28/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406528
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 04/23/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693433
Principal investigator 1 Boehringer Ingelheim International GmbH $34.80 04/23/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693435
Principal investigator 1 Boehringer Ingelheim International GmbH $4,715.20 04/17/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693409
Principal investigator 1 Boehringer Ingelheim International GmbH $4,827.20 04/17/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693411
Principal investigator 1 Boehringer Ingelheim International GmbH $3,810.80 04/17/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693413
Principal investigator 1 Boehringer Ingelheim International GmbH $1,695.40 04/17/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693415
Principal investigator 1 Genentech, Inc. $3,056.00 04/11/2025 Non-covered Recipient Entity
MEDICAL CTR OPHTHALMOLOGY ASSOC LLP
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211623224
Principal investigator 1 Boehringer Ingelheim International GmbH $4,180.40 04/10/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693403
Principal investigator 1 Boehringer Ingelheim International GmbH $1,695.40 04/02/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693405
Principal investigator 1 Boehringer Ingelheim International GmbH $4,715.20 04/02/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693407
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693417
Recipient F. Hoffmann-La Roche AG $561.67 03/31/2025 Covered Recipient Physician Predictors of extended treatment intervals in patients with DME treated with faricimab in the phase 3 YOSEMITE/RHINE trials No dispute reported 06/30/2026 1211537776
Recipient F. Hoffmann-La Roche AG $565.91 03/31/2025 Covered Recipient Physician Clinical Features of Eyes that Participated in the RHONE-X Trial No dispute reported 06/30/2026 1211537780
Principal investigator 1 Genentech, Inc. $3,321.00 03/26/2025 Non-covered Recipient Entity
MEDICAL CTR OPHTHALMOLOGY ASSOC LLP
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211623228
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 03/25/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693393
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 03/25/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693395
Principal investigator 1 Boehringer Ingelheim International GmbH $1,131.50 03/25/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693397
Principal investigator 1 Boehringer Ingelheim International GmbH $245.92 03/25/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693399
Principal investigator 1 Boehringer Ingelheim International GmbH $6.10 03/25/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693401
Recipient Regeneron Pharmaceuticals, Inc. $3,831.92 03/12/2025 Covered Recipient Physician EYLEA CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184122709
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693419
Recipient Regeneron Pharmaceuticals, Inc. $408.07 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184122697
Recipient Regeneron Pharmaceuticals, Inc. $150.00 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184122699
Recipient Regeneron Pharmaceuticals, Inc. $81.75 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184122701
Recipient Regeneron Pharmaceuticals, Inc. $21.80 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184122703
Recipient Regeneron Pharmaceuticals, Inc. $79.00 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184122705
Recipient Regeneron Pharmaceuticals, Inc. $21.80 03/01/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184122707
Recipient Regeneron Pharmaceuticals, Inc. $919.00 02/28/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184122693
Recipient Regeneron Pharmaceuticals, Inc. $184.25 02/28/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184122695
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,337.40 02/27/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225402935
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,337.40 02/27/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225403159
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,978.30 02/27/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404369
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 02/25/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693391
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693457
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,337.40 01/30/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404367
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,337.40 01/30/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225404726
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,337.40 01/30/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates
BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion No dispute reported 06/30/2026 1225406732
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 01/27/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693385
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 01/27/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693387
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 01/27/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693389
Principal investigator 1 Ocular Therapeutix, Inc. $8,604.00 01/24/2025 Non-covered Recipient Entity
MEDICAL CENTRE OPHTHALMOLOGY ASSOCIATES
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250234892
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Medical Center Ophthalmology Associates Admin Office
CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy No dispute reported 06/30/2026 1220693383